Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03531008 · ClinicalTrials.gov registry record
Human Epilepsy Project 2: Resistant Focal Seizures Study
A clinical trial, sponsored by Epilepsy Foundation of America.
- Completed
- Registry status
- 157
- Enrollment target
NCT03531008: Completed study, sponsored by Epilepsy Foundation of America.
NCT03531008 is a clinical trial that has completed, run by Epilepsy Foundation of America. The registered enrollment target is 157 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03531008 has completed, sponsored by Epilepsy Foundation of America.
- COMPLETED
- Registry status
- 157 participants
- Enrollment target
Study Summary
The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in health status, healthcare costs, quality of life, and biomarkers of epilepsy severity and treatment response.
Primary Outcome
To prospectively quantify seizure frequency over a 24 month period in a cohort of adults with treatment resistant focal epilepsy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2022-09-30 |
What the finished NCT03531008 record still lists
NCT03531008 is an observational study that tracks outcomes without assigning an intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03531008 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03531008 about?
NCT03531008 is a clinical study titled "Human Epilepsy Project 2: Resistant Focal Seizures Study". The HEP2 study is designed to better understand the challenges of living with focal seizures that do not respond to medication, by following 205 people with medication-resistant focal epilepsy over two years to measure changes in health status, healthcare costs, quality of life, and biomarkers of ep...
What is the current status of trial NCT03531008?
This trial is currently completed. The enrollment target is 157 participants. The study started on 2018-05-07. Estimated completion is 2022-09-30.
Who is sponsoring clinical trial NCT03531008?
This trial is sponsored by Epilepsy Foundation of America, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI